RecruitingNCT03320304
About this title
A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression.
Read the official source — NCT03320304Official study titleA Global PRospective, Multi-cEnter, ObServational Post-markeT Study tO Assess shoRt, Mid and Long-term Effectiveness and Efficiency of VNS Therapy® as Adjunctive Therapy in reaL-world patIents With diFficult to Treat dEpression.
Multiple locations, including ViennaDepressionObservational studyAges 18+
- Countries
- United Kingdom, Belgium, Austria, + 1 other
- Sponsor
- LivaNova
RecruitingNCT05511363
About this title
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Read the official source — NCT05511363Official study titleA Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
Multiple locations, including OrangeSchizophreniaMedication studyAges 55–90
- Countries
- United States, France, United Kingdom, + 10 others
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
RecruitingNCT06126224
About this title
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Read the official source — NCT06126224Official study titleA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
Multiple locations, including StuartSchizophreniaMedication studyAges 55–90
- Countries
- United States, Canada, United Kingdom, + 11 others
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
RecruitingNCT06540833
About this title
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Read the official source — NCT06540833Official study titleA Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Efficacy, Safety, and Tolerability of ITI 1284 in Patients With Psychosis Associated With Alzheimer's Disease
Multiple locations, including AnaheimSchizophreniaMedication studyAges 55+
- Countries
- United States, Bulgaria, Croatia, + 7 others
- Sponsor
- Intra-Cellular Therapies, Inc.
RecruitingNCT06887192
About this title
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
Read the official source — NCT06887192Official study titleA Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis
Multiple locations, including PhoenixSchizophreniaMedication studyAges 55–90
- Countries
- United States, France, Canada, + 12 others
- Sponsor
- MapLight Therapeutics
RecruitingNCT06929273
What is this study about?This extension study evaluates the long-term safety and tolerability of KarXT for mania or mania with mixed features in people living with bipolarity type I.
Multiple locations, including BentonvilleBipolarityMedicationAges 18–65
- Countries
- United States, Australia, France, + 17 others
- Sponsor
- Bristol-Myers Squibb (Pharmaceutical company)
RecruitingISRCTN55669001
Official study titleA randomized controlled study to evaluate a digital intervention for the treatment of adjustment disorders in adults
Original registry wording; source language not specified.
In GermanyAdjustment disorderInterventional studyAges 18–100
- Countries
- Germany
- Sponsor
- Elona Health GmbH
RecruitingNCT06585787
About this title
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Read the official source — NCT06585787Official study titleA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
Multiple locations, including GilbertSchizophreniaMedication studyAges 55–90
- Countries
- United States, France, Belgium, + 21 others
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
RecruitingNCT06947941
About this title
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Read the official source — NCT06947941Official study titleA Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Psychosis Associated With Alzheimer's Disease
Multiple locations, including GilbertSchizophreniaMedication studyAges 55–90
- Countries
- United States, Australia, Canada, + 2 others
- Sponsor
- Bristol-Myers Squibb (Pharmaceutical company)
RecruitingNCT07221877
Official study titleA 12-month Open-label, Phase 4 Multicenter Safety Study to Evaluate the Effect of KarXT on Voiding Dynamics and Urological Safety
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Bristol-Myers Squibb (Pharmaceutical company)
RecruitingNCT07610473
What is this study about?This study evaluates the safety and effectiveness of DT-101 for people with depression.
Multiple locations, including PhoenixDepressionMedication studyAges 18–75
- Countries
- United States
- Sponsor
- Draig Therapeutics Ltd
RecruitingNCT07300969
What is this study about?This study evaluates the safety and effectiveness of DT-101 for people with depression.
Multiple locations, including BentonvilleDepressionMedication studyAges 18–75
- Countries
- United States, United Kingdom, Bulgaria, + 2 others
- Sponsor
- Draig Therapeutics Ltd
